November 2025 Veradermics initiated enrollment in a Phase 2/3 clinical trial evaluating VDPHL01, an extended-release oral minoxidil candidate for female pattern hair loss. The program represented an advancement toward developing oral prescription treatments specifically designed for women experiencing pattern hair loss.
October 2025 Pelage Pharmaceuticals secured USD 120 million in Series B financing to accelerate development of its regenerative hair loss treatment platform. The funding supported advancement of clinical programs, expansion of research activities, and preparation for late-stage clinical trials targeting hair follicle regeneration.
July 2025 Sun Pharmaceutical Industries launched LEQSELVI™ (deuruxolitinib) tablets in the U.S. market for the treatment of severe alopecia areata. The product launch expanded Sun Pharma’s dermatology portfolio and introduced a new oral treatment option for patients with autoimmune-related hair loss.
July 2025 Sun Pharmaceutical Industries and Incyte Corporation reached an agreement related to LEQSELVI™, enabling Sun Pharma to commercialize deuruxolitinib for specific non-oncology indications, including alopecia areata, in the U.S. market.